The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
The closing price of Enliven Therapeutics Inc (NASDAQ: ELVN) was $21.37 for the day, down -4.13% from the previous closing price of $22.29. In other words, the price has decreased by -$4.13 from its previous closing price. On the day, 0.58 million shares were traded.
Ratios:
Our analysis of ELVN’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 21.06 and its Current Ratio is at 21.06. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, BTIG Research on December 13, 2024, initiated with a Buy rating and assigned the stock a target price of $42.
On September 09, 2024, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $37. On June 11, 2024, Robert W. Baird started tracking the stock assigning a Outperform rating and target price of $32.Robert W. Baird initiated its Outperform rating on June 11, 2024, with a $32 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jun 03 ’25 when Lyssikatos Joseph P sold 7,500 shares for $20.03 per share. The transaction valued at 150,220 led to the insider holds 977,688 shares of the business.
Kintz Samuel sold 7,500 shares of ELVN for $150,352 on Jun 03 ’25. The PRESIDENT AND CEO now owns 965,392 shares after completing the transaction at $20.05 per share. On Jun 03 ’25, another insider, Kintz Samuel, who serves as the Officer of the company, bought 7,500 shares for $19.14 each.
Stock Price History:
Over the past 52 weeks, ELVN has reached a high of $30.03, while it has fallen to a 52-week low of $13.30. The 50-Day Moving Average of the stock is 16.18%, while the 200-Day Moving Average is calculated to be -4.45%.
Shares Statistics:
A total of 49.04M shares are outstanding, with a floating share count of 32.21M. Insiders hold about 34.36% of the company’s shares, while institutions hold 73.72% stake in the company.
Earnings Estimates
Enliven Therapeutics Inc (ELVN) is currently under the scrutiny of 1 analysts, each contributing to the ongoing evaluation of its stock.The consensus estimate for the next quarter is -$0.4, with high estimates of -$0.4 and low estimates of -$0.4.
Analysts are recommending an EPS of between -$1.59 and -$1.59 for the fiscal current year, implying an average EPS of -$1.59. EPS for the following year is -$1.64, with 1.0 analysts recommending between -$1.64 and -$1.64.
